CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

September 7, 2026
3 min

The Medicine Maker

Overview

Administering CAR T cells before glioblastoma surgery improved tumor control and survival compared with treatment after surgery in mouse models.

Background

Glioblastoma remains a challenging malignancy, with surgical resection as the primary treatment followed by radiotherapy and chemotherapy. Recent studies have explored the timing of CAR T cell administration, suggesting that preoperative treatment may be more beneficial than postoperative approaches. Understanding the immune changes post-surgery is crucial for optimizing treatment strategies.

Data Highlights

Study Group	Treatment Timing	Tumor Control	Survival
Preoperative CAR T	3 days before surgery	Improved	Prolonged
Postoperative CAR T	During surgery	Less effective	Reduced

Key Findings

Preoperative CAR T cell administration resulted in better tumor control and prolonged survival compared to postoperative administration.
Surgery induced changes in the tumor microenvironment, increasing TREM2 levels associated with immunosuppressive myeloid cells.
T cells showed exhaustion-like phenotypes following surgical resection.
CAR T cells delivered before surgery maintained stronger effector function and better distribution around the tumor margins.
Combining GD2-targeting CAR T cells with TREM2-targeting cells showed modest survival improvement but required careful timing consideration.